Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | YTB323 |
Synonyms | |
Therapy Description |
YTB323 are autologous T cells that express a chimeric antigen receptor (CAR) targeting CD19, potentially resulting in cytotoxicity against CD19-expressing tumor cells (PMID: 37249512). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YTB323 | YTB-323|YTB 323|CD19-specific CAR T cells YTB323 | CD19 Immune Cell Therapy 62 | YTB323 are autologous T cells that express a chimeric antigen receptor (CAR) targeting CD19, potentially resulting in cytotoxicity against CD19-expressing tumor cells (PMID: 37249512). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03960840 | Phase I | Ibrutinib + YTB323 YTB323 | CD19-specific CAR-T Cells in CLL/SLL and DLBCL | Recruiting | USA | ITA | FRA | ESP | DEU | AUT | AUS | 1 |